Rise based on fundamentals5 Sep 2023 18:14
Oversold and undervalued. Very few pharmas have a phase 3 multinational study under their belts. Slightly underpowered leading to crippling sell off. It is safe, well tolerated and with good evidence of efficacy. Bread crumbs being dropped by the company and Covid is in ascendancy again. Time for a re-rate.